Important note: Information in this article was accurate in octubre 2007. The state of the art may have changed since the publication date.
 |
PI Perspective - periódico del tratamiento de Project Inform 44 - octubre, 2007
Como se reportó en el número de octubre de 2007 de la publicación “AIDS”, un estudio que examinaba el uso del Reyataz (atazanavir) como monoterapia fue suspendido tempranamente debido a la alta tasa de avance virológico. Los investigadores trataron de observar si existía una conexión entre los niveles de reyataz medidos en la sangre y el riesgo de un resurgimiento virológico, y no encontraron ninguna. Lo que sí encontraron fue una conexión entre la bilirrubina y los resultados del tratamiento con Reyataz.
Ha habido algún interés entre los investigadores de estudiar ciertos medicamentos contra el VIH para ser utilizados como monoterapia. Este interés surge principalmente de la investigación del Dr. Joel Gath sobre la monoterapia con Kaletra— la cual se encontró bastante exitosa, pero no tanto como la terapia antiretroviral de alta potencia tradicional. El Reyataz despertó interés debido a su combinación de potencia y alta barrera de resistencia. Este estudio sugiere que el riesgo de un avance virológico prematuro en la monoterapia con Reyataz es inaceptablemente alto.
071001
PI071005
©2007. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1985, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS , or the party credited as the provider of the content.